History | Rituximab for the first-line treatment of stage III-IV follicular lymphoma | Guidance | NICE

History

A list of downloadable documents created during development.

Background information

TA243 Follicular lymphoma - rituximab (review): review decision - August 2014 information
TA243 Follicular lymphoma - rituximab (review): appendix a - decision paper presented to the Institute's Guidance Executive ^{PDF 107 KB} 26 August 2014
TA243 Follicular lymphoma - rituximab (review): review proposal - June 2014 information
Appendix A: matrix of stakeholders ^{PDF 99 KB} 16 June 2014
Appendix B: proposal paper presented to the Institute's Guidance Executive ^{PDF 444 KB} 16 June 2014

Follicular lymphoma - rituximab (review): EIA

Follicular lymphoma - rituximab (review): EIA ^{PDF 75 KB} 25 January 2012

Follicular lymphoma - rituximab (review): final appraisal determination

Follicular lymphoma - rituximab (review): final appraisal determination information
Follicular lymphoma - rituximab (review): final appraisal determination ^{PDF 232 KB} 01 December 2011
Follicular lymphoma - rituximab (review): response to consultee, commentator and public comments on the appraisal consultation document (ACD) ^{PDF 162 KB} 01 December 2011
Follicular lymphoma - rituximab (review): consultee and commentator comments on the ACD
Follicular lymphoma - rituximab (review): comments from School of Health and Related Research ^{PDF 52 KB} 01 December 2011
Follicular lymphoma - rituximab (review): comments from Roche Pharmaceuticals ^{PDF 175 KB} 01 December 2011
Follicular lymphoma - rituximab (review): comments from Lymphoma association and Leukaemia Care ^{PDF 61 KB} 01 December 2011
Follicular lymphoma - rituximab (review): comments from Royal College of Physicians ^{PDF 204 KB} 01 December 2011
Follicular lymphoma - rituximab (review): comments from Healthcare Improvement Scotland ^{PDF 62 KB} 01 December 2011
Follicular lymphoma - rituximab (review): comments from Commissioning Support Appraisals Service ^{PDF 376 KB} 01 December 2011
Follicular lymphoma - rituximab (review): expert comments - Parker (clinical expert) ^{PDF 47 KB} 01 December 2011
Follicular lymphoma - rituximab (review): comments on the ACD received from the public through the NICE website ^{PDF 31 KB} 01 December 2011

Follicular lymphoma - rituximab (review): appraisal consultation

Follicular lymphoma - rituximab (review): appraisal consultation
Follicular lymphoma - rituximab (review): appraisal consultation document information
Follicular lymphoma - rituximab (review): evaluation report
Follicular lymphoma - rituximab (review): overview ^{PDF 236 KB} 05 September 2011
Follicular lymphoma - rituximab (review): assessment report
Follicular lymphoma - rituximab (review): assessment report ^{PDF 2.64 MB} 05 September 2011
Follicular lymphoma - rituximab (review): erratum to assessment report ^{PDF 29 KB} 05 September 2011
Follicular lymphoma - rituximab (review): consultee and commentator comments on the assessment report
Follicular lymphoma - rituximab (review): Roche ^{PDF 92 KB} 05 September 2011
Follicular lymphoma - rituximab (review): Healthcare Improvement Scotland
Follicular lymphoma - rituximab (review): Healthcare Improvement Scotland comments 1 ^{PDF 34 KB} 05 September 2011
Follicular lymphoma - rituximab (review): Healthcare Improvement Scotland comments 2 ^{PDF 150 KB} 05 September 2011
Follicular lymphoma - rituximab (review): response to consultee and commentator comments on the assessment report
Follicular lymphoma - rituximab (review): Assessment Group response to comments from Roche ^{PDF 16 KB} 05 September 2011
Follicular lymphoma - rituximab (review): Assessment Group response to Healthcare Improvement Scotland ^{PDF 37 KB} 05 September 2011
Follicular lymphoma - rituximab (review): Roche executive summary ^{PDF 96 KB} 05 September 2011
Follicular lymphoma - rituximab (review): non-manufacturer submission
Follicular lymphoma - rituximab (review): Lymphoma Association ^{PDF 37 KB} 05 September 2011
Follicular lymphoma - rituximab (review): Royal College of Pathologists and British Society for Haematology ^{PDF 32 KB} 05 September 2011
Follicular lymphoma - rituximab (review): NHS North of Tyne ^{PDF 30 KB} 05 September 2011
Follicular lymphoma - rituximab (review): expert written personal statements
Follicular lymphoma - rituximab (review): Barton ^{PDF 1.13 MB} 05 September 2011
Follicular lymphoma - rituximab (review): Jolliffe ^{PDF 19 KB} 05 September 2011
Follicular lymphoma - rituximab (review): Parker ^{PDF 29 KB} 05 September 2011

Follicular lymphoma - rituximab (review): assessment report consultation

Follicular lymphoma - rituximab (review): assessment report consultation ^{PDF 3.74 MB} 25 May 2011

Follicular lymphoma - rituximab (review): protocol

Follicular lymphoma - rituximab (review): protocol ^{PDF 120 KB} 04 October 2010

Follicular lymphoma - rituximab (review): final scope

Follicular lymphoma - rituximab (review): final scope ^{PDF 69 KB} 13 September 2010

Follicular lymphoma - rituximab (review): final matrix

Follicular lymphoma - rituximab (review): final matrix ^{PDF 49 KB} 10 September 2010

Follicular lymphoma - rituximab (review): response to consultee and commentator comments on the draft scope

Follicular lymphoma - rituximab (review): response to consultee and commentator comments on the draft scope ^{PDF 106 KB} 13 September 2010

Follicular lymphoma - rituximab (review): response to consultee and commentator comments on the provisional matrix of consultees and commentators

Follicular lymphoma - rituximab (review): response to consultee and commentator comments on the provisional matrix of consultees and commentators ^{PDF 29 KB} 13 September 2010

Follicular lymphoma - rituximab (review): appendix A - draft scope

Follicular lymphoma - rituximab (review): appendix A - draft scope ^{PDF 97 KB} 27 April 2010

Follicular lymphoma - rituximab (review): appendix B - provisional matrix of consultees and commentators

Follicular lymphoma - rituximab (review): appendix B - provisional matrix of consultees and commentators ^{PDF 39 KB} 29 April 2010